Loading clinical trials...

AI Models vs Non-Invasive Fibrosis Scores in MAFLD Diagnosis | Clinical Trials | Clareo Health

COMPLETED

AI Models vs Non-Invasive Fibrosis Scores in MAFLD Diagnosis

Assessing the Utility of AI Models in MAFLD Diagnosis: Comparison With Traditional Non-Invasive Fibrosis Scores.

NCT07305636•Tanta University

Summary

This study evaluates the accuracy of artificial intelligence (AI) models using FibroScan and clinical data to predict hepatic fibrosis in Egyptian patients with metabolic-associated fatty liver disease (MAFLD). The performance of the AI models will be compared with conventional noninvasive fibrosis scores (FIB-4, APRI, NAFLD fibrosis score, and FAST). The goal is to improve early, noninvasive diagnosis of fibrosis and reduce reliance on liver biopsy.

Eligibility

Age

0 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•\- Adults ≥18 years.
•Diagnosed with MAFLD according to international criteria (hepatic steatosis with metabolic dysfunction).
•Valid FibroScan evaluation with available LSM and CAP values.

Exclusion Criteria

•Excessive alcohol intake (\>30 g/day for men, \>20 g/day for women).
•Chronic viral hepatitis (HBV or HCV).
•Autoimmune hepatitis.
•Known malignancy.
•Pregnancy.
•Refusal to participate.

Locations (1)

Faculty of Medicine

Tanta, Egypt

Key Dates

Start Date

May 13, 2025

Primary Completion Date

August 30, 2025

Completion Date

November 30, 2025

Last Updated

December 26, 2025

Enrollment

522

ACTUAL participants

Conditions

MAFLDAI (Artificial Intelligence)

An Explainable Neuroradiologist Artificial Intelligence Assistance System for Brain CT and MRI

NCT07167043

Central Nervous System DiseaseMRI+3 more

View study

ACTIVE_NOT_RECRUITING

Knowledge, Perception, Usage And Concerns Of Artificial Intelligence Applications In Periodontology

NCT06951152

AI (Artificial Intelligence)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 26, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

AI Models vs Non-Invasive Fibrosis Scores in MAFLD Diagnosis

Inclusion Criteria

Exclusion Criteria

An Explainable Neuroradiologist Artificial Intelligence Assistance System for Brain CT and MRI

Knowledge, Perception, Usage And Concerns Of Artificial Intelligence Applications In Periodontology

Evaluation of Dora Care for Supporting Fracture Liaison Services (FLS)

A Prospective Validation Study of Radiomics in the Differential Diagnosis of Uterine Leiomyoma and Uterine Sarcoma

Comparison of a Handheld Elastography Device With iLivTouch in Chronic Liver Disease Patients

Impact of Fluid Status on Liver Elastography and T1-mapping Results in Patients Undergoing CMR.